Preclinical studies demonstrate that RT enhances CD8+ T cell activity by upregulating MHC class I expression on tumor cells, promoting dendritic cell maturation, and releasing tumor antigens and damage-associated molecular patterns (DAMPs) that prime cytotoxic T-lymphocytes [1,2]. Here, CD8A is linked to neoplasm.